PRESCIENT THERAPEUTICS LIMITED — Director's Dealing 2011

Nov 22, 2011

==> picture [190 x 74] intentionally omitted <==

ASX Announcement (441)

23 November 2011

Appendix 3B – Registration of Ordinary Shares Appendix 3Y – Change of Director’s Interests

Please find attached a copy of the Appendix 3B released to the market.

Key points of the issue are:

• 7,247,403 fully Paid Ordinary Shares upon settlement of the Director Deferred Remuneration in accordance with shareholder approvals of 18 November 2011.

As a result there are now 222,072,152 fully Paid Ordinary Shares in the Company on issue and 7,890,227 VHLG Convertible Notes outstanding.

Yours sincerely,

==> picture [115 x 70] intentionally omitted <==

John Morrison Company Secretary Virax Holdings Limited

Virax Holdings Limited ABN 56 006 569 106 Suite 220 89 High Street Kew Victoria Australia 3101 Telephone +61 (0) 3 9854 6230 Facsimile+61 (0) 3 9853 5134 www.virax.com.au email: virax@virax.com.au

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Application for quotation of additional securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Virax Holdings Limited

ABN

56 006 569 106

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of+securities issued or to be issued 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) 4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 7 Dates of entering +securities into uncertificated holdings or despatch of certificates	(i) Ordinary Fully Paid Shares
	(i) 7,247,403 Fully Paid Ordinary Shares
	(i) 1.371 cents per ordinary share in accordance with 18 November 2011 shareholder approval on resolutions 4, 5 and 6.
	(i) Fully Paid ordinary shares rank pari passu with existing shares
	(i) 1.371 cents per ordinary share;
	(i) Issued in settlement of deferred director remuneration as approved by shareholders on 18 November 2011.
	23 November 2011

• See chapter 19 for defined terms.

• 8 Number and[+] class of all[+] securities quoted on ASX ( including the securities in clause 2 if applicable)

• 9 Number and +class of all +securities not quoted on ASX ( including the securities in clause 2 if applicable)

• 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Number	~~+~~Class
222,072,152 7,890,227	Fully Paid Ordinary Shares (VHL) Convertible Notes (VHLG)
Number	~~+~~Class
3,491,333	Unlisted Options
Fully Paid Ordinary shares rank pari passu with existing shares Note and Option holders are not entitled to Dividends. Upon conversion/exercise the shares rank Pari Passu with existingshares.

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required? 12 Is the issue renounceable or non-renounceable? 13 Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A

• See chapter 19 for defined terms.

24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders 25 If the issue is contingent on +security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do +security holders sell their entitlements _in full_through a broker? 31 How do +security holders sell_part_of their entitlements through a broker and accept for the balance? 32 How do +security holders dispose of their entitlements (except by sale through a broker)? 33 +Despatch date	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities ( tick one )

• (a) Securities described in Part 1

• (b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

• See chapter 19 for defined terms.

36 If the[+] securities are[+] equity securities, a distribution schedule of the additional[+] securities setting out the number of holders in the categories

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

• 38 Number of securities for which[+] quotation is sought

• 39 Class of[+] securities for which quotation is sought

• 40 Do the[+] securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:

• the date from which they do

• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

• 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

• Number +Class

• 42 Number and[+] class of all[+] securities quoted on ASX ( including the securities in clause 38)

• See chapter 19 for defined terms.

Quotation agreement

• 1 Quotation of our additional[+] securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• There is no reason why those[+] securities should not be granted[+] quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

• If we are a trust, we warrant that no person has the right to return the[+] securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before[+] quotation of the[+] securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 23 November 2011 ~~(Director/~~ Company Secretary)

Print name: John Morrison

• See chapter 19 for defined terms.

Notice of Change of Director’s Interest (Appendix 3Y Notice) Notice No. 07

Name of entity:	Virax Holdings Limited
ABN No:	56 006 569 106

We, Virax Holdings Limited, give ASX the following information under listing rule 3.19A.1 and as agent for the Director for the purposes of section 205G of the Corporation Act.

Name of Director	Michael Humphris
Date of last notice	19 July 2011	Last Notice No. 6

Part 1 – Change of Director’s relevant interest in securities*

Direct or indirect interest	Direct	Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest
Date of change	23 November 2011
Class	Fully Paid Ordinary Shares - VHL	Convertible Notes	Unlisted Options
No. of securities held prior to change	7,661,375	Nil	1,000,000
Number acquired	2,982,471A
Number disposed
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$ 40,875.00A
No. of securities held after change	10,643,846	Nil	1,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Note A_: _Issued pursuant to Resolution 4 assed at Virax’s Annual General Meeting held on 18 November 2011 - Ordinary Shares (VHL) issued in consideration for $40,875.00 of deferred Directors fees.

Notice of Change of Director’s Interest (Appendix 3Y Notice) Notice No. 07

Part 2 – Change of Director’s interests in contracts*

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change: Note: Details are only required for a contract in relation to which the interest has changed. Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Interest after change

If insufficient space please provide attachment and insert attachment number in appropriate space.

Signed

	Date 23 November 2011
_____	____

John Morrison Company Secretary Virax Holdings Limited

Notice of Change of Director’s Interest (Appendix 3Y Notice) Notice No. 08

Name of entity:	Virax Holdings Limited
ABN No:	56 006 569 106

We, Virax Holdings Limited, give ASX the following information under listing rule 3.19A.1 and as agent for the Director for the purposes of section 205G of the Corporation Act.

Name of Director	Ian Pyman
Date of last notice	19 July 2011	Last Notice No. 7

Part 1 – Change of Director’s relevant interest in securities*

Direct or indirect interest	Indirect	Indirect	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances givingrise to the relevant interest	IP Projects Pty Ltd (_as trustee for the_Pyman Family Superannuation Fund)
Date of change	22 November 2011
Class	Fully Paid Ordinary Share – VHL	Convertible Notes	Unlisted Options
No. of securities held prior to change	5,381,699	Nil	750,000
Number acquired	2,187,145A
Number disposed			375,000
Value/Consideration Note: If consideration is non-cash, provide details and estimatedvaluation	$ 29,975.00 A
No. of securities held after change	7,568,844	Nil	750,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Note A: Issued pursuant to Resolution 5 passed at Virax’s Annual Meeting held on 18 November 2011 - Ordinary Shares (VHL) issued in consideration for $29,975.00 of deferred Directors fees.

Notice of Change of Director’s Interest (Appendix 3Y Notice) Notice No. 08

Part 2 – Change of Director’s interests in contracts*

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change: Note: Details are only required for a contract in relation to which the interest has changed. Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Interest after change

If insufficient space please provide attachment and insert attachment number in appropriate space.

Signed

	Date 23 November 2011
_____	____

John Morrison Company Secretary Virax Holdings Limited